NPC1 and Parkinson disease: In line with previous evidence [15], rotenone-treated cells displayed intracellular cholesterol overload, accompanied by reduced NPC1 expression and impaired lysosomal localization, indicative of disrupted cholesterol trafficking in the PD-like phenotype.